$ Value
$1.7M
Shares
20,571
Price
$81
Filed
Dec 3
Insider
Name
WENDER JOSEPH H
Title
—
CIK
0001073384
Roles
Transaction Details
Transaction Date
2025-12-01
Code
S
Table
Non-Derivative
Ownership
Indirect
Equity Swap
No
Shares After
43,464
Footnotes
Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 26, 2024. | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.11 to $81.11 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.12 to $81.435 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
Filing Info
WENDER JOSEPH H's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2025-12-01 | IONS | ▼ | $1.7M |
| 2025-12-01 | IONS | ▼ | $603K |
| 2025-11-18 | IONS | M | $391K |
| 2025-11-18 | IONS | M | $0 |
| 2025-10-31 | IONS | ▼ | $842K |
| 2025-10-30 | IONS | ▼ | $179K |
| 2025-10-30 | IONS | ▼ | $610K |
| 2025-10-30 | IONS | ▼ | $441K |
| 2025-10-01 | IONS | ▼ | $1.1M |
| 2025-09-03 | IONS | ▼ | $674K |
Other Insiders at IONS (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| PARSHALL B LYNNE | — | $381K | 2026-04-15 |
|
BENNETT C FRANK
EVP, Chief Scientific Officer
|
— | $7.5M | 2026-02-02 |
|
HOUGEN ELIZABETH L
EVP, Finance & CFO
|
— | $582K | 2026-01-30 |
| KLEIN JOSEPH III | — | $1.7M | 2026-04-01 |
|
Monia Brett P
Chief Executive Officer
|
— | $5.2M | 2026-01-30 |
|
O'NEIL PATRICK R.
EVP CLO & General Counsel
|
— | $516K | 2026-01-30 |
|
Swayze Eric
EVP Research
|
— | $512K | 2026-01-30 |
|
Jenne Kyle
EVP, Chf GL Pdt Str Ofcr
|
— | $368K | 2026-04-16 |
|
Baroldi Joseph
EVP, Chief Business Officer
|
— | $858K | 2026-04-16 |
|
Schneider Eugene
EVP, Chf Clinical Develop Ofcr
|
— | $516K | 2026-01-30 |
|
Birchler Brian
EVP, Corp and Development Ops
|
— | $586K | 2026-04-16 |
|
Devers Shannon L.
EVP, Chief Human Resources Ofc
|
— | $459K | 2026-04-02 |